Current Pharmaceutical Design

Top Research Topics at Current Pharmaceutical Design?

Internal medicine, Pharmacology, Immunology, Disease and Endocrinology are the subjects of interest in the journal. In addition to Internal medicine research, Current Pharmaceutical Design aims to explore topics under Diabetes mellitus, Oncology and Cardiology. Drug is a major topic of Pharmacology research presented in it.

Drug research discussed connects with the study of Drug delivery. The Immunology study featured in it draws connections with the study of Cancer research. It is mostly focused on Cancer research, specifically Angiogenesis.

Some problems in Disease that were presented in it overlapped with concepts under Bioinformatics and Intensive care medicine.

• Internal medicine (17.08%)
• Pharmacology (14.80%)
• Immunology (13.53%)

What are the most cited papers published in the journal?

• Mean Platelet Volume: A Link Between Thrombosis and Inflammation? (767 citations)
• Natural and synthetic coumarin derivatives with anti-inflammatory/ antioxidant activities. (685 citations)
• Internet addiction: a systematic review of epidemiological research for the last decade. (674 citations)

Research areas of the most cited articles at Current Pharmaceutical Design:

The journal articles focus largely on the fields of Biochemistry, Internal medicine, Pharmacology, Immunology and Endocrinology. The works on Immunology tackled in the most cited articles bring together disciplines like Cancer research and Disease. Receptor and Neuroscience are some topics wherein Endocrinology research discussed in the most cited papers has an impact.

What topics the last edition of the journal is best known for?

• Internal medicine
• Gene
• Enzyme

The previous edition focused in particular on these issues:

The main research concerns discussed in the journal are Disease, Internal medicine, Intensive care medicine, Cancer and Cancer research. Research on Disease addressed in the journal frequently intersections with the field of Bioinformatics. Topics in Internal medicine were tackled in line with various other fields like Endocrinology, Oncology and Cardiology.

The Cancer research presented places emphasis on topics like Metastasis, Breast cancer and Colorectal cancer. Current Pharmaceutical Design explores issues in Cancer research which can be linked to other research areas like Carcinogenesis, Cancer cell, Lung cancer and microRNA.

The most cited articles from the last journal are:

• Anti-Neuroinflammatory Potential of Polyphenols by Inhibiting NF-κB to Halt Alzheimer's Disease. (10 citations)
• Natural agents modulating ACE-2: A review of compounds with potential against SARS-CoV-2 infections. (9 citations)
• Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease. (9 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Current Pharmaceutical Design (based on the number of publications) are:

• Dimitri P. Mikhailidis (66 papers) published 2 papers at the last edition the same number as at the previous edition,
• Mohammad Amjad Kamal (60 papers) published 11 papers at the last edition, 3 less than at the previous edition,
• Dimitris Tousoulis (54 papers) published 1 paper at the last edition, 6 less than at the previous edition,
• Emilio Jirillo (53 papers) absent at the last edition,
• Alexander N. Orekhov (47 papers) published 5 papers at the last edition, 4 more than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Current Pharmaceutical Design (based on the number of publications) are:

• National and Kapodistrian University of Athens (113 papers) published 8 papers at the last edition, 11 less than at the previous edition,
• University of Bari (93 papers) published 3 papers at the last edition, 2 more than at the previous edition,
• University of Palermo (92 papers) published 3 papers at the last edition, 5 less than at the previous edition,
• Sapienza University of Rome (84 papers) published 3 papers at the last edition, 1 less than at the previous edition,
• King Abdulaziz University (81 papers) published 17 papers at the last edition, 5 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 7.24% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 15.60% were posted by at least one author from the top 10 institutions publishing in the journal. Another 2.36% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 8.27% of all publications and 73.76% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Connectivity to Other Fields of Study

The wide spectrum of topics discussed in the Current Pharmaceutical Design journal represents a vast intersection with other fields of study, reflecting the multidisciplinary nature of pharmaceutical research. It serves to deepen the understanding of pertinent issues across the gamut of medicinal study and other related disciplines. For instance, many studies of pharmaceutical design exist in harmony with other scientific investigations such as chemical engineering, biochemistry, and even the rapidly evolving field of AI in healthcare.

Expanding more on intersectional research areas, it has been noticed that some of the methodologies and findings in pharmaceutical design have been significantly applicable and influential in the nursing field. To understand this relation better, one can delve into online resources like the best online nursing programs in Minnesota, which highlight how teachings and breakthroughs from a pharmaceutical research landscape can be beneficial in nursing education and practice. The synergy between these disciplines contributes to the overall progress in healthcare and medicine.

Conclusively, the continual dialogue between pharmaceutical design and other relevant fields brings to light novel pathways and possibilities towards healthcare solutions of the future. Thus, it is noteworthy for academia and industry experts to consider these intersections as they navigate through their research and professional practices.